|
Home > Archive > Pathology > September 2006 > Biphosphonate and deferoxamine regresses soft tissue calcifications
You are viewing an archived Text-only version of the thread.
To view this thread in it's original format and/or if you want to reply to
this thread please [click here]
| Author |
Biphosphonate and deferoxamine regresses soft tissue calcifications
|
|
| ironjustice@aol.com 2006-09-29, 4:30 pm |
| Successful treatment of soft tissue calcifications in uremia.
Sikole A, Stojkovski L, Cakalaroski K, Stojcev N, Amitov V, Polenakovic
M
Prilozi. 2006; 27(1): 145-50
The appearance of soft tissue calcifications in patients with chronic
renal failure has been recognised as one of the serious complications
of uremia. An elevated serum calcium-phosphate product has almost
invariably been detected, although the exact mechanisms of
precipitation are still not fully understood. Among the factors
responsible for triggering the precipitation process are:
hyperphosphatemia, secondary hyperparathyroidism, hypercalcemia,
treatment with vitamin D3, etc. Phosphate binders have been used to
prevent, among other things, soft tissue calcifications, and
parathyroidectomy has most frequently been applied as the therapy of
choice, once precipitation of calcium salts has occurred. We present a
case of soft tissue calcifications in the gluteal regions of a chronic
haemodialysis female patient. The therapy we chose was a combination of
biphosphonate and deferoxamine. The patient was treated for two months.
The regression of the soft tissue calcifications was very significant,
as registered both clinically and radiologically. The exact mechanism
by which this reversal was achieved needs further investigation. Key
words: Kidney failure chronic, haemodialysis, soft tissue
calcifications, therapy.
Abstract =B7 PubMed FullText =B7 SFX =B7 GS Clip Export InterDB =B7
Terms Related =B7 Graph Cites =B7 Tag
Definitions of deferoxamine on the Web:
An iron-chelating agent that removes iron from tumors by inhibiting DNA
synthesis and causing cancer cell death. It is used in conjunction with
other anticancer agents in pediatric neuroblastoma therapy.
www.seniormag.com/conditions/cancer...rglossary/d.htm
Iron-chelating agent used therapeutically to treat acute iron
intoxication or chronic iron overload in transfusion-dependent
patients. May also be used to treat hemochromatosis in patients such as
anemics who cannot tolerate phlebotomy. It forms a water-soluble
complex with iron that is excreted in urine and feces (see chelation
therapy).
www.cdc.gov/hemochromatosis/training/glossary.htm
A drug used in iron intoxication, chronic iron overload after multiple
blood transfusions and hemochromatosis, if phebotomies are not
possible. An investigational use is treatment of aluminium overload in
renal failure. Registered trade mark in USA Desferal.
www.gastrolab.net/dicted.htm
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING=20
http://tinyurl.com/zk9fk
| |
| ironjustice@aol.com 2006-09-29, 9:28 pm |
|
ironjustice@aol.com wrote:
> Successful treatment of soft tissue calcifications in uremia.
> Sikole A, Stojkovski L, Cakalaroski K, Stojcev N, Amitov V, Polenakovic
> M
> Prilozi. 2006; 27(1): 145-50
>
> The appearance of soft tissue calcifications in patients with chronic
> renal failure has been recognised as one of the serious complications
> of uremia. An elevated serum calcium-phosphate product has almost
> invariably been detected, although the exact mechanisms of
> precipitation are still not fully understood. Among the factors
> responsible for triggering the precipitation process are:
> hyperphosphatemia, secondary hyperparathyroidism, hypercalcemia,
> treatment with vitamin D3, etc. Phosphate binders have been used to
> prevent, among other things, soft tissue calcifications, and
> parathyroidectomy has most frequently been applied as the therapy of
> choice, once precipitation of calcium salts has occurred. We present a
> case of soft tissue calcifications in the gluteal regions of a chronic
> haemodialysis female patient. The therapy we chose was a combination of
> biphosphonate and deferoxamine. The patient was treated for two months.
> The regression of the soft tissue calcifications was very significant,
> as registered both clinically and radiologically. The exact mechanism
> by which this reversal was achieved needs further investigation. Key
> words: Kidney failure chronic, haemodialysis, soft tissue
> calcifications, therapy.
>
>
> Abstract =B7 PubMed FullText =B7 SFX =B7 GS Clip Export InterDB =B7
> Terms Related =B7 Graph Cites =B7 Tag
>
> Definitions of deferoxamine on the Web:
>
> An iron-chelating agent that removes iron from tumors by inhibiting DNA
> synthesis and causing cancer cell death. It is used in conjunction with
> other anticancer agents in pediatric neuroblastoma therapy.
> www.seniormag.com/conditions/cancer...rglossary/d.htm
>
> Iron-chelating agent used therapeutically to treat acute iron
> intoxication or chronic iron overload in transfusion-dependent
> patients. May also be used to treat hemochromatosis in patients such as
> anemics who cannot tolerate phlebotomy. It forms a water-soluble
> complex with iron that is excreted in urine and feces (see chelation
> therapy).
> www.cdc.gov/hemochromatosis/training/glossary.htm
>
> A drug used in iron intoxication, chronic iron overload after multiple
> blood transfusions and hemochromatosis, if phebotomies are not
> possible. An investigational use is treatment of aluminium overload in
> renal failure. Registered trade mark in USA Desferal.
> www.gastrolab.net/dicted.htm
>
> Who loves ya.
> Tom
>
>
> Jesus Was A Vegetarian!
> http://jesuswasavegetarian.7h.com
>
>
> Man Is A Herbivore!
> http://tinyurl.com/a3cc3
>
>
> DEAD PEOPLE WALKING
> http://tinyurl.com/zk9fk
"The therapy we chose was a combination of
biphosphonate and deferoxamine. The regression of the soft tissue
calcifications was very significant"
Sooo .. since BOTH .. of the above .. drugs are .. iron chelators ...
then one might think .. iron .. may be .. involved ..
<<snip>>
Bisphosphonates have antioxidant properties as iron chelators
<<snip>>
Antioxidant effect of bisphosphonates and simvastatin on chondrocyte
lipid peroxidation.
Dombrecht EJ, De Tollenaere CB, Aerts K, Cos P, Schuerwegh AJ, Bridts
CH, Van Offel JF, Ebo DG, Stevens WJ, De Clerck LS
Biochem Biophys Res Commun. 2006 Jul 28;
The objective of this study was to evaluate the effect of
bisphosphonates (BPs) and simvastatin on chondrocyte lipid
peroxidation. For this purpose, a flow cytometrical method using
C11-BODIPY(581/591) was developed to detect hydroperoxide-induced lipid
peroxidation in chondrocytes. Tertiary butylhydroperoxide (t-BHP)
induced a time and concentration dependent increase in chondrocyte
lipid peroxidation. Addition of a Fe(2+)/EDTA complex to t-BHP or
hydrogen peroxide (H(2)O(2)) clearly enhanced lipid peroxidation. The
lipophilic simvastatin demonstrated a small inhibition in the
chondrocyte lipid peroxidation. None of three tested BPs (clodronate,
pamidronate, and risedronate) had an effect on chondrocyte lipid
peroxidation induced by t-BHP. However, when Fe(2+)/EDTA complex was
added to t-BHP or H(2)O(2), BPs inhibited the lipid peroxidation
process varying from 25% to 58%. This study demonstrates that BPs have
antioxidant properties as iron chelators, thereby inhibiting the
chondrocyte lipid peroxidation. These findings add evidence to the
therapeutic potential of bisphosphonates and statins in rheumatoid
arthritis.
---------------------------------------------------------------------------=
=AD----------
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
|
| |
|
|